Skip to main content

Table 2 Data extraction

From: Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

Study design  
 • Study name, author and year of publication
 • Study design
 • Study period
 • Inclusion/exclusion criteria
 • Country
 • Settings
 • HCV treatment regimen
 • Definition of cirrhosis detection
 • HCV RNA quantification limit
 • Population analysed
 • Attrition and selection bias
 
Trial characteristics  
 • Type of publication
 • Type of study
 • Treatment regimen
 • Treatment duration
 • Ribavirin
 
Patient characteristics  
 • Proportion of men
 • Ethnicity (Caucasian/Asian)
 • Body-mass index
 • GT3 sample size at baseline
 • Treatment-naïve patients
 • CKD stages
 • Dialysis
 • Renal transplantation
 • Concomitant treatment with proton pump inhibitor (PPI)
 
Disease characteristics  
 • HCV RNA
 • Baseline resistance-associated variants/substitutions (RAV)
 • Human immunodeficiency virus (HIV) co-infection
 • Liver transplantation
 • Cirrhosis (compensated/decompensated)
 • MELD score
 • Child-Pugh score
 • Liver disease severity (F0/F1/F2/F3/F4)
 
Treatment outcomes  
 • Rates of SVR (SVR4, SVR12, SVR24 and/or unspecified SVR)
 • 95% confidence interval (calculated from SVR data, where reported)
 • Rates of relapse after treatment
 • Type of relapse
 • Treatment discontinuation
 • Serious adverse events (SAEs)
 
  1. CKD chronic kidney disease, GT3 genotype 3, HCV hepatitis C virus, MELD model for end-stage liver disease, SVR sustained virological response